Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation
June 23, 2023Ryan ScottThe combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter trans
Updated on: October 15,2023
Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation
June 23, 2023Ryan ScottThe combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter trans
Updated on:October 15,2023
